605 Neoadjuvant Vidutolimod (vidu) and Nivolumab (nivo) Results in MPR and Immune Activation in High-Risk Resectable Melanoma (MEL): Final Phase II Clinical Trial ResultsArivarasan Karunamurthy,Joe-Marc Chauvin,Robert Morrison,Yulong Bai,Jie Sun,Hong Wang,Douglas Hartman,Julie Stein,Christopher Deitrick,Riyue Bao,Jagjit Singh,Quanquan Ding,Wentao Gao,Drew Hurd,Ornella Pagliano,Amy Rose,Yana Najjar,Jason Luke,David Mauro,Arthur Krieg,James Wooldridge,Dmitri Bobilev,John Kirkwood,Janis Taube,Hyun Jung Park,Hassane Zarour,Diwakar DavarRegular and Young Investigator Award Abstracts（2022）引用 2|浏览27AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
